Broad Spectrum Chemotherapy: A Novel Approach Using Beta-Galactosidase Activated Pro-Drugs
Annual summary rept. 1 Mar 2005-28 Feb 2006
TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER
Pagination or Media Count:
Gene therapy shows promise for treating prostate cancer and is being exploited in several clinical trials. A major hurdle is establishing a method of verifying transgene activity in situ. beta-galactosidase beta-gal was historically the most popular reporter gene for molecular biology. I have introduced a novel concept for further exploration of gene therapy using beta-galactosidase to activate a broad-spectrum chemotherapeutic to assess the efficacy of the pro-drugs in vitro and explore growth delay in animal models. I also have developed a new beta-galactosidase molecular reporter for MRI spectra, which can be used to detection of lacZ gene expression in vivo.
- Medicine and Medical Research